|
KMID : 1009020140120010037
|
|
Clinical Psychopharmacology and Neuroscience
2014 Volume.12 No. 1 p.37 ~ p.40
|
|
|
Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder
|
|
Atake Kiyokazu
Yoshimura Reiji
Hori Hikaru
Katsuki Asuka
Ikenouchi-Sugita Atsuko
Umene-Nakano Wakako
Nakamura Jun
|
|
|
Abstract
|
|
|
Objective: We investigated the effects of duloxetine on the plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor (BDNF) in 64 patients with major depressive disorder (MDD).
Methods: Major depressive episode was diagnosed using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-fourth edition (DSM-IV) according to the DSM-IV text revision (DSM-IV-TR) criteria. The severity of depression was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD-17). Blood sampling and clinical evaluation were performed on days 0, 28, and 56.
Results: Duloxetine treatment for 8 weeks significantly increased the plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels but not the homovanillic acid (HVA) levels in responders with MDD.
Conclusion: These results imply that noradrenaline plays an important role in alleviating depressive symptoms.
|
|
|
KEYWORD
|
|
|
Duloxetine, 3-Methoxy-4-hydroxyphenylglycol, Homovanillic acid, Major depressive disorder, Brain-derived neurotrophic factor
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|